211 related articles for article (PubMed ID: 35012368)
21. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome.
Volchenkov R; Brun JG; Jonsson R; Appel S
Arthritis Res Ther; 2013; 15(5):R114. PubMed ID: 24025795
[TBL] [Abstract][Full Text] [Related]
22. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
[TBL] [Abstract][Full Text] [Related]
23. B-cell hyperactivity in primary Sjögren's syndrome.
Kroese FG; Abdulahad WH; Haacke E; Bos NA; Vissink A; Bootsma H
Expert Rev Clin Immunol; 2014 Apr; 10(4):483-99. PubMed ID: 24564507
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus.
Szabó K; Papp G; Szántó A; Tarr T; Zeher M
Clin Exp Immunol; 2016 Jan; 183(1):76-89. PubMed ID: 26358223
[TBL] [Abstract][Full Text] [Related]
25. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome.
Alunno A; Petrillo MG; Nocentini G; Bistoni O; Bartoloni E; Caterbi S; Bianchini R; Baldini C; Nicoletti I; Riccardi C; Gerli R
Rheumatology (Oxford); 2013 Aug; 52(8):1387-96. PubMed ID: 23674818
[TBL] [Abstract][Full Text] [Related]
27. Elevated EPSTI1 promote B cell hyperactivation through NF-κB signalling in patients with primary Sjögren's syndrome.
Sun JL; Zhang HZ; Liu SY; Lian CF; Chen ZL; Shao TH; Zhang S; Zhao LL; He CM; Wang M; Zhang W; Chen H; Zhang FC
Ann Rheum Dis; 2020 Apr; 79(4):518-524. PubMed ID: 32114510
[TBL] [Abstract][Full Text] [Related]
28. Constitutive STAT3 activation in peripheral CD3(+) cells from patients with primary Sjögren's syndrome.
Ramos HL; Valencia-Pacheco G; Alcocer-Varela J
Scand J Rheumatol; 2008; 37(1):35-9. PubMed ID: 18189193
[TBL] [Abstract][Full Text] [Related]
29. Catalpol ameliorates Sjögren's Syndrome by modulating interplay of T and B cells.
Lin R; Hao D; Dong Y; Wang Y
Biomed Pharmacother; 2020 Mar; 123():109806. PubMed ID: 31951976
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cells derived from human dental follicle modulate the aberrant immune response in atopic dermatitis.
Zibandeh N; Genc D; Ozgen Z; Duran Y; Goker K; Baris S; Ergun T; Akkoc T
Immunotherapy; 2021 Jul; 13(10):825-840. PubMed ID: 33955241
[TBL] [Abstract][Full Text] [Related]
31. Dental follicle mesenchymal stem cells ameliorated glandular dysfunction in Sjögren's syndrome murine model.
Genç D; Bulut O; Günaydin B; Göksu M; Düzgün M; Dere Y; Sezgin S; Aladağ A; Bülbül A
PLoS One; 2022; 17(5):e0266137. PubMed ID: 35511824
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.
Abughanam G; Elkashty OA; Liu Y; Bakkar MO; Tran SD
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557796
[TBL] [Abstract][Full Text] [Related]
33. The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren's Syndrome.
Verstappen GM; Gao L; Pringle S; Haacke EA; van der Vegt B; Liefers SC; Patel V; Hu Y; Mukherjee S; Carman J; Menard LC; Spijkervet FKL; Vissink A; Bootsma H; Kroese FGM
Front Immunol; 2021; 12():681941. PubMed ID: 34295332
[TBL] [Abstract][Full Text] [Related]
34.
Wang J; She C; Li Z; Tang N; Xu L; Liu Z; Liu B
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):28-36. PubMed ID: 31876196
[No Abstract] [Full Text] [Related]
35. The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren's Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution.
Szabó K; Jámbor I; Szántó A; Horváth IF; Tarr T; Nakken B; Szodoray P; Papp G
Front Immunol; 2021; 12():639975. PubMed ID: 33815392
[TBL] [Abstract][Full Text] [Related]
36. Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and Suppressing Plasma Cells.
Xing Y; Li B; He J; Hua H
Front Immunol; 2022; 13():871096. PubMed ID: 35444638
[TBL] [Abstract][Full Text] [Related]
37. Immunobiology of T Cells in Sjögren's Syndrome.
Yao Y; Ma JF; Chang C; Xu T; Gao CY; Gershwin ME; Lian ZX
Clin Rev Allergy Immunol; 2021 Feb; 60(1):111-131. PubMed ID: 32390096
[TBL] [Abstract][Full Text] [Related]
38. Altered phenotype and Stat1 expression in Toll-like receptor 7/8 stimulated monocyte-derived dendritic cells from patients with primary Sjögren's syndrome.
Vogelsang P; Karlsen M; Brun JG; Jonsson R; Appel S
Arthritis Res Ther; 2014 Aug; 16(4):R166. PubMed ID: 25113744
[TBL] [Abstract][Full Text] [Related]
39. Alleviating effect of paeoniflorin-6'-O-benzene sulfonate in antigen-induced experimental Sjögren's syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway.
Chen X; Zhang P; Liu Q; Zhang Q; Gu F; Xu S; Körner H; Wu H; Wei W
Int Immunopharmacol; 2020 Mar; 80():106199. PubMed ID: 31955068
[TBL] [Abstract][Full Text] [Related]
40. Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome.
Sanosyan A; Daien C; Nutz A; Bollore K; Bedin AS; Morel J; Zimmermann V; Nocturne G; Peries M; Guigue N; Gottenberg JE; Van de Perre P; Mariette X; Tuaillon E
Front Immunol; 2019; 10():1153. PubMed ID: 31191532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
